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Abstract
Toll-like receptors (TLRs) play crucial roles in the induc-
tion of innate immune responses by recognising pathogen-
associated molecular patterns. The engagement of TLRs
by pathogens results in induction of co-stimulatory mol-
ecules that facilitate a specific immune response and also in
the induction of pro-inflammatory proteins that will
promote the elimination of pathogens from the body.
TLRs employ many of the same signalling components as
the type I interleukin (IL)-1 receptor (IL-1R). This is
hardly surprising since the intracellular regions of TLRs
and the IL-1R share a conserved Toll/IL-1R homology
domain (TIR) that allows the receptors to recruit the
intracellular TIR-containing adaptor protein Myd88. The
latter then activates IL-1R-associated kinases that in turn
recruit well-characterised downstream effectors culmi-
nating in activation of MAP kinases and transcription
factors such as NFB and AP-1. Since glucocorticoids are
known to target the latter transcription factors and the
MAP kinase cascades, this commentary highlights the
likely crucial importance of Toll-like receptor signalling
pathways as key targets for mediating the anti-
inflammatory and immunosuppressive effects of steroids.
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Toll-like receptors (TLRs) and immunity
Human TLRs are key components in innate immune
responses due to their ability to recognise pathogen-
associated molecules (reviewed by Krutzik et al. 2001).
Many of the TLRs have defined functions in the host
defence system. As examples, TLR2 recognises peptido-
glycan and bacterial lipoprotein from Gram-positive bac-
teria (Aliprantis et al. 1999, Brightbill et al. 1999, Takeuchi
et al. 1999), TLR3 mediates responses to double-stranded
RNA (Alexopoulou et al. 2001), TLR4 is involved in
recognition of Gram-negative lipopolysaccharide (LPS)
(Poltorak et al. 1998, Chow et al. 1999, Hoshino et al.
1999, Qureshi et al. 1999, Takeuchi et al. 1999), TLR-5
recognises bacterial flagellin (Hayashi et al. 2001) and
TLR9 functions as a receptor for bacterial DNA contain-
ing CpG motifs (Hemmi et al. 2000). Some TLRs, such
as TLR2 and -6 also show functional co-operativity
(Ozinsky et al. 2000). The engagement of TLRs by
pathogenic components results in induction of co-
stimulatory molecules that facilitate T-cell activation and
pro-inflammatory proteins that effect elimination of the
pathogen from the body (Medzhitov et al. 1997).
TLR/interleukin-1 (IL-1) signalling and NFB
TLRs employ many of the same signalling components as
the type I IL-1 receptor (IL-1RI) (O’Neill & Greene
1998) (Fig. 1) by virtue of a conserved cytoplasmic
Toll/IL-1R homology domain (TIR). The latter is
important in initiating various signalling pathways,
especially that regulating the transcription factor NFB.
The latter exists in the cytosol of resting cells as a homo-
or heterodimer of proteins of the Rel family of transcrip-
tion factors (Ghosh et al. 1998). The transcriptional activity
of the Rel proteins is tightly regulated by their association
with members of the inhibitory IB family (e.g. IB-,
IB- and IB-´) that sequester nuclear factor kappaB
(NFB) in the cytosol. TLRs and IL-1R cause phosphor-
ylation of IB on two specific N-terminal serines by the
IB kinases (IKKs), IKK and IKK, which form a large
multiprotein complex with a scaffold protein called
NEMO (IKK). The phosphorylation of IB proteins
represents a signal for polyubiquitination followed by their
degradation via the 26S proteasome (May & Ghosh 1998,
Karin & Ben-Neriah 2000). This allows for translocation
of NFB to the nucleus, where it activates genes encoding
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inflammatory proteins and co-stimulatory molecules. Thus
the IKKs are crucial regulators of NFB and much effort
has probed the upstream signalling components employed
by TLRs and IL-1R in regulating IKK activity.
The TIR domain plays a crucial role in transducing
signals from TLRs and IL-1RI (Fig. 1). Thus the binding
of IL-1 to IL-1RI causes association with another TIR
domain-containing protein, IL-1R-accessory protein
(Greenfeder et al. 1995, Wesche et al. 1997a). This
receptor complex then recruits the intracellular TIR-
containing adapter protein Myd88 (Burns et al. 1998).
TLRs can directly associate with Myd88 (Medzhitov et al.
1998) and other TIR domain-containing adapter proteins
such as MyD88 adapter-like/TIR domain-containing
adapter protein (Fitzgerald et al. 2001, Horng et al. 2001)
and TIR domain-containing adapter inducing IFN-/
TIR-containing adaptor molecule (Yamamoto et al. 2002,
Oshiumi et al. 2003). These adapter proteins subsequently
recruit and activate members of the IL-1R-associated
kinase (IRAK) family (Muzio et al. 1997, Wesche et al.
1997b, Kobayashi et al. 2002, Li et al. 2002, Suzuki et al.
2002). IRAK is recruited to Myd88 in association with
another protein termed Toll-interacting protein (Tollip)
(Burns et al. 2000). IRAK associates with Myd88 via the
homophilic interaction of their death domains. IRAK also
contains a kinase domain but the kinase activity is not
required for NFB activation but may be required for
other pathways such as the p38 MAP kinase (MAPK)
cascade (Knop & Martin 1999, Schmidt et al. 2001). The
IRAK–Myd88 association triggers hyperphosphorylation
of IRAK by itself (Cao et al. 1996) and/or by other
additional kinases (Li et al. 1999), leading to its dissociation
from Myd88 and Tollip and its interaction with the
downstream adaptor tumour necrosis factor (TNF)
receptor-associated factor 6 (TRAF-6) (Burns et al. 2000).
The phosphorylation of IRAK also ultimately leads to its
degradation by proteasomes and this may be a regulatory
mechanism by which cells become desensitised after
prolonged activation of IL-RI and TLRs (Yamin & Miller
1997, Li et al. 2000). The interaction of IRAK with
TRAF-6 leads to activation of transforming growth factor-
-activating kinase (TAK1) (Ninomiya-Tsuji et al. 1999).
IRAK is essential in this activation process since it
promotes the translocation of TAK1 binding protein 2
(TAB2) from the membrane to the cytosol where TAB2
interacts with TRAF-6 and bridges the association of
TRAF-6 with TAK1 (Takaesu et al. 2000, 2001). The
latter, with the help of another TAK1-binding protein,
Figure 1 Toll-like receptor signalling and lead targets for glucocorticoids. The signalling molecules generally employed by TLRs in
mediating activation of the transcription factors NFB and AP-1 and the MAPKs are indicated. Some additional signalling molecules in
these pathways have been omitted for the sake of clarity. The lead targets that may be subject to inhibition by activated GR are encircled
in red. PAMPs, pathogen-associated molecular patterns.
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TAB1, becomes activated and in turn activates NFB-
inducing kinase (NIK) (Ninomiya-Tsuji et al. 1999). NIK
can then activate NFB through phosphorylation and
activation of the IKKs (Ling et al. 1998, Nakano et al.
1998). However, the role of NIK has recently been
equivocated with analysis of NIK knockout mice and
alymphoplasia mice that contain a point mutation in NIK
showing no defect in activation of NFB by TNF, IL-1
and LPS (Shinkura et al. 1999, Yin et al. 2001). Interest-
ingly IKKs may also be activated by MAPK/ERK kinase
kinase 1 (MEKK-1) that is activated by TRAF-6 via a
novel adaptor protein termed ECSIT (Kopp et al. 1999).
Thus TRAF-6 appears to act as a bifurcation point to
activate the TAK1 and MEKK-1 pathways, both of which
activate NFB.
TLR/IL-1 signalling and MAPKs
In addition to NFB activation, IL-1RI and TLRs can
also initiate MAPK signalling cascades and activate mul-
tiple transcription factors, including AP-1 and Elk-1. Thus
IL-1 and LPS induce phosphorylation of p38, ERK1/2
and JNK (Freshney et al. 1994, Rouse et al. 1994, Derijard
et al. 1995, Lin et al. 1995, Ulevitch & Tobias 1995).
Whilst the mechanisms by which the MAPKs are acti-
vated by IL-1R1 and TLRs are incompletely understood,
several upstream regulators have been identified. Interest-
ingly, as described above, such regulators also play integral
roles in mediating activation of NFB (Fig. 1). Thus
TAK1/TAB1 can activate the MAPKKs MKK3/6 and
MKK4, which in turn activate p38 and JNK respectively
(Ninomiya-Tsuji et al. 1999). In addition MEKK-1 can
also activate the JNK pathway by phosphorylating MKK4
(Xia et al. 1998).
Transcription factors as targets for glucocorticoids
Whilst the molecular mechanisms underlying the anti-
inflammatory and immunosuppressive effects of glucocor-
ticoids are complex and incompletely understood, the
signalling pathways described above for TLRs are likely
to emerge as lead targets for mediating such effects. A
succinct overview of the known molecular effects of
glucocorticoids gives significant credence to this proposal.
The primary target for glucocorticoids is a specific
intracellular glucocorticoid receptor (GR) (Beato et al.
1995). The engagement of GR by glucocorticoids pro-
motes its dissociation from the 90 kDa heat shock protein
and translocation into the nucleus. The liganded GR binds
as a dimer to DNA by recognising specific palindromic
sequences known as glucocorticoid response elements
(GREs) (Luisi et al. 1991). The binding of GR to GREs
can induce the transcription of genes whose promoters are
in close proximity to GREs, by facilitating recruitment of
co-activator complexes (such as CREB-binding protein
(CBP)/p300) and RNA polymerase II. By this process
glucocorticoids can directly promote the expression of
anti-inflammatory proteins such as lipocortin, IL-1R
antagonist and IL-10 (Adcock & Caramori 2001). It is also
interesting to note that glucocorticoids can directly induce
the expression of IB-, the inhibitor of NFB (Almawi
& Melemedjian 2002). The author has shown this phe-
nomenon to be cell-type specific (Bourke & Moynagh
1999), but it is still worth emphasising that in responsive
cells the induction of IB- by glucocorticoids is likely to
have a negative influence on TLR signalling. Additional
mechanisms by which glucocorticoids regulate NFB are
discussed below.
Whilst the direct induction of anti-inflammatory
proteins by glucocorticoids is a significant contributory
mechanism to their clinical anti-inflammatory effects, the
pleiotropic ability of glucocorticoids to inhibit the expres-
sion of a plethora of pro-inflammatory proteins is likely to
be of crucial importance (Barnes 1995). Thus glucocorti-
coids inhibit the expression of an array of cytokines
(including IL-1 and TNF), chemokines and leukocyte
adhesion molecules. In general the promoters of the genes
encoding these proteins lack GREs and thus gene repres-
sion is not dependent on GR–GRE interaction. Instead
repression is mediated by inhibitory effects of activated
GR on transcription factors that are known to promote the
expression of the pro-inflammatory proteins. Two of the
best characterised transcription factors that are known
targets for activated GR are NFB and AP-1. In addition
to the positive regulation of IB- expression, as described
above, activated GR is also known to directly associate
with AP-1 and the p65 subunit of NFB (Adcock &
Caramori 2001). Such interactions lead to reduced associ-
ation of AP-1 and NFB with the co-activator CBP
resulting in inhibition of their transactivation potential. A
recent report has suggested a related but novel mechanism
underlying GR repression of pro-inflammatory gene
expression in which GR inhibits histone acetylation by
directly inhibiting CBP-associated histone acetyltrans-
ferase activity and by actively recruiting a histone deacety-
lase complex (Ito et al. 2000). Such histone deacetylation
will prevent unwinding of DNA from histone complexes
and so limit access of transcription factors such as NFB
and AP-1 to their binding sites, resulting in inhibition
of expression of pro-inflammatory genes. Furthermore,
another report suggests an additional specific mechanism
for the inhibitory effects of GR on NFB. Thus GR has
been shown to inhibit NFB by interfering with serine-2
phosphorylation of the C-terminal domain of RNA
polymerase II, resulting in reduced recruitment of the
latter to NFB-regulated promoter regions (Nissen &
Yamamoto 2000). A complex picture thus emerges of the
regulatory effects of activated GR on the transcription
factors NFB and AP-1. However, it is intuitively obvious
that glucocorticoids may target TLR signalling since TLR
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signalling culminates in activation of NFB and AP-1
(Fig. 1).
MAPKs as targets for glucocorticoids
Whilst NFB and AP-1 are key targets for GR, it is also
apparent that regulation of these transcription factors is not
the exclusive basis for GR repression of inflammatory
genes. The MAPK signalling pathways play important
roles in promoting inflammatory gene expression and it has
emerged that these pathways are also prone to regulation
by glucocorticoids. Dexamethasone has been shown to
inhibit activation of ERK1/2, JNK and p38 MAPKs
(Caelles et al. 1997, Swantek et al. 1997, Gonzalez et al.
1999, Lasa et al. 2001) and repress inflammatory gene
expression. As an example GR blocks the JNK signalling
pathway resulting in lack of phosphorylation of c-Jun on
serine-63 and -73 and ultimately inhibition of AP-1 and
repression of gene expression (Caelles et al. 1997). This
represents another mechanism by which GR can regulate
AP-1 activity and is distinct from the direct GR–AP-1
association described above. Furthermore since JNK is
required for LPS stimulation of TNF translation, the
inhibition of JNK by GR results in reduced TNF trans-
lation in response to LPS (Swantek et al. 1997). Since the
latter is recognised by TLR-4 it is apparent that JNK in
the TLR-4 signalling pathway is a key target for gluco-
corticoids. However, the other MAPKs are also likely to
play roles in mediating anti-inflammatory effects of glu-
cocorticoids on TLR signalling. Thus LPS is well known
to induce cyclooxygenase 2 and dexamethasone has been
shown to destabilise cyclooxygenase 2 mRNA by inhib-
iting the phosphorylation and activity of p38 MAPK (Lasa
et al. 2001). The inhibition of the MAPKs by glucocorti-
coids is mediated by an increased expression and decreased
degradation of the MAPK phosphatase-1 (Kassel et al.
2001). Overall a convincing picture emerges of MAPK
pathways playing key roles as targets for glucocorticoids.
The employment of MAPK pathways by TLRs again
emphasises the obvious relevance of TLR signalling
pathways as targets for glucocorticoids (Fig. 1).
Likely consequences of regulation of TLR
signalling by glucocorticoids
The above discussion highlights TLR signalling pathways
as lead targets for glucocorticoids. The global use of the
transcription factors NFB and AP-1 and the MAPK
pathways by the various TLRs strongly hints that all of the
TLR signalling pathways will be subject to interference by
glucocorticoids. This has important functional conse-
quence in terms of widespread suppression of the innate
immune response to a variety of pathogens. TLRs are
strategically located at the host–pathogen interface and
serve to recognise a number of molecules that are
expressed by pathogens and not the host. This recognition
triggers a complex cascade of intracellular signalling path-
ways, as described above, that will ultimately promote the
expression of pro-inflammatory proteins such as IL-1 and
TNF. The latter orchestrate the inflammatory response
and thus the inhibition of TLR signalling by glucocorti-
coids will repress IL-1 and TNF expression and this is
likely to make a major contribution to dampening the
inflammatory response. Since the latter is a crucial com-
ponent of the innate immunity, it is clear that the
regulation of TLR signalling by glucocorticoids lies at the
heart of their immunosuppressive and anti-inflammatory
properties. The targeting of TLR signalling by steroids
probably contributes to the compromised immune status of
individuals on long-term use of steroids for the treatment
of inflammatory diseases. The blunting of TLR signalling
by steroids will interfere with the initial recognition phase
of the immune response and will dampen the innate
response to pathogens. However, the fallout of inhibition
of TLR signalling is not restricted to innate immunity.
The triggering of TLRs, such as TLR-4 by LPS, also
induces the expression of co-stimulatory molecules on
antigen-presenting cells and this is a key process in
initiating a specific immune response (Medzhitov et al.
1997). The signalling pathways employed by TLRs in
promoting the expression of co-stimulatory molecules are
common to the above transduction systems used in induc-
ing pro-inflammatory gene expression. Thus the regu-
lation of these pathways by glucocorticoids will repress the
expression of co-stimulatory molecules and suppress the
specific immune response.
In summary, glucocorticoids have the potential to
inhibit the intracellular signalling pathways employed by
TLRs. The latter act at the crossroads of innate and
adaptive immunity and thus the paralysis of TLR signal-
ling is likely to be central in manifesting the remarkable
immunosuppressive effects of glucocorticoids.
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